Compare RELY & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELY | ARQT |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.3B |
| IPO Year | 2021 | 2020 |
| Metric | RELY | ARQT |
|---|---|---|
| Price | $15.98 | $22.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $24.13 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 3.2M | 1.2M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 263.16 | 88.79 |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $1,635,147,000.00 | $376,072,000.00 |
| Revenue This Year | $21.82 | $34.46 |
| Revenue Next Year | $19.08 | $29.77 |
| P/E Ratio | $49.31 | ★ N/A |
| Revenue Growth | 29.37 | ★ 91.34 |
| 52 Week Low | $12.08 | $11.86 |
| 52 Week High | $24.63 | $31.77 |
| Indicator | RELY | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 52.70 | 38.07 |
| Support Level | $15.62 | $19.60 |
| Resistance Level | $17.81 | $27.26 |
| Average True Range (ATR) | 0.61 | 0.90 |
| MACD | -0.21 | -0.12 |
| Stochastic Oscillator | 30.25 | 19.56 |
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.